2026 Autoimmune Summit: Key Research Highlights

The Autoimmune Association hosted its 2026 Autoimmune Community Summit virtually from October 14–16, bringing together researchers, clinicians, patient advocates, and people living with autoimmune disease to discuss scientific advances, emerging treatments, and challenges in diagnosis and care.

Across three days, presentations explored how advances in understanding immune-system activity, genetic risk, environmental exposures, and individual differences could help improve autoimmune disease diagnosis and treatment.

AI, Biomarkers, and the Future of Autoimmune Diagnosis

Several speakers discussed efforts to better understand autoimmune diseases at the molecular level.

Dajiang Liu, PhD, of Penn State College of Medicine, highlighted research using artificial intelligence (AI) and genetic data to investigate lupus risk and identify potential treatments. Marjolein Klaassen, MD, PhD, of MIT, discussed how multi-omics research is revealing distinct immune patterns among people with the same autoimmune diagnosis, including Sjögren disease.

Julius Birnbaum, MD, of the University of Pittsburgh Medical Center, explored why autoimmune diseases can be difficult to diagnose, especially when symptoms overlap with other conditions or conventional antibody tests are inconclusive. He emphasized the importance of recognizing patterns across symptoms and medical histories rather than relying on any single test.

GAI EXPERT PERSPECTIVE A Closer Look at Brain Fog and Autoimmune Disease Dr. Birnbaum has also shared his expertise with GAI in Understanding Brain Fog in Autoimmune Disease, examining another complex aspect of autoimmune illness: the cognitive difficulties that patients may experience and the challenges of understanding their underlying causes. Read the Article ↗

GLP-1 Medications, Metabolism, and Inflammation

Researchers examined the relationship between metabolic health and inflammatory disease, including growing interest in GLP-1-based medications.

Alexis Ogdie, MD, of the University of Pennsylvania, highlighted findings from the TOGETHER-PsA clinical trial, which found that adding tirzepatide to the biologic ixekizumab improved joint disease activity and weight-related outcomes compared with ixekizumab alone in adults with active psoriatic arthritis and overweight or obesity.

Other discussions explored the importance of preserving muscle mass and strength during weight loss and the need for further research into how metabolic medications affect immune function.

RELATED RESEARCH FROM GAI GLP-1 Medications and Autoimmune Disease How might GLP-1 medications influence inflammation and autoimmune disease? GAI’s article, GLP-1 Receptor Agonists and Autoimmune Diseases, examines emerging research, potential anti-inflammatory effects, and important questions that remain about their use in autoimmune conditions. Read the Article ↗

Environmental Exposures and Immune-System Changes

Megan Smithmyer, PhD, of Benaroya Research Institute, discussed research identifying distinct immune profiles in healthy individuals and examining how environmental exposures, including wildfire smoke, may affect immune-cell activity.

Adam Schiffenbauer, MD, of the National Institutes of Health, also explored potential environmental contributors to autoimmune disease, including pollution, infections, ultraviolet exposure, and the microbiome.

Fatigue, Neurological Symptoms, and Women’s Health

Other presentations addressed symptoms and health concerns that can be particularly challenging for people living with autoimmune disease.

Mark Zielinski, PhD, discussed experimental research into inflammatory signaling between the immune system and brain, including pathways that may contribute to fatigue and sleep disruption. Amanda Piquet, MD, examined autoimmune conditions affecting the nervous system and the complexities of evaluating cognitive symptoms.

Women’s health sessions addressed lupus pregnancy planning, maternal autoantibodies, menopause, and the difficulty of distinguishing hormonal changes from autoimmune disease symptoms. Jill Buyon, MD, discussed research into identifying and preventing pregnancy complications associated with specific autoantibodies, while Nanette Santoro, MD, explored the effects of menopause on inflammatory and autoimmune conditions.

Connecting Research With Patient Care

Alongside scientific presentations, the summit addressed practical aspects of managing autoimmune disease, including nutrition, exercise, treatment access, health insurance, and navigating complex healthcare systems.

Together, the discussions highlighted both the progress being made in autoimmune research and the challenges that remain in bringing scientific advances into clinical practice. From identifying individual immune patterns to improving access to care, the summit reinforced the importance of connecting research discoveries with the needs and experiences of people living with autoimmune disease.

Reference

Autoimmune Association, 2026 Autoimmune Community Summit, October 14–16, 2026.